Clinical Efficacy and Safety of Statins in Managing Cardiovascular Risk

Overview

Journal Vasc Health Risk Manag

Publisher Dove Medical Press

Specialty Cardiology & Vascular Diseases

Date 2008 Jun 20

PMID 18561510

Citations 50

Authors

Navin K Kapur

Kiran Musunuru

Affiliations

Soon will be listed here.

Abstract

Since their introduction in the 1980s, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have emerged as the one of the best-selling medication classes to date, with numerous trials demonstrating powerful efficacy in preventing cardiovascular outcomes. As our understanding of low-density lipoprotein cholesterol (LDL-C) and atherosclerosis continues to grow, the concept of 'lower is better' has corresponded with a more is better' approach to statin-based therapy. This review provides a detailed understanding of the clinical efficacy and safety of statins with a particular emphasis on the third generation drug, rosuvastatin.

Citing Articles

Left portal vein thrombosis as an unusual complication following acute cholecystitis: case report and literature review.

Almudaiheem F, Aljabali M, Ali B, Alanazi M J Surg Case Rep. 2025; 2025(3):rjaf118.

PMID: 40062222 PMC: 11886354. DOI: 10.1093/jscr/rjaf118.

The association between energy-adjusted dietary inflammatory index and 10-year cardiovascular risk: Fasa adult cohort study.

Sepehrinia M, Pourmontaseri H, Naghizadeh M, Vahid F, Hebert J, Homayounfar R Food Sci Nutr. 2024; 12(8):5530-5537.

PMID: 39139971 PMC: 11317652. DOI: 10.1002/fsn3.4181.

Lipid Accumulation in Increases Cell Damage in Co-Cultured Cells.

Liao C, Chen C, Shin J, Lin W, Chen C, Chu C Microorganisms. 2023; 11(6).

PMID: 37375084 PMC: 10305000. DOI: 10.3390/microorganisms11061582.

Jumpstarting Health With a 15-Day Whole-Food Plant-Based Program.

Friedman S, Barnett C, Franki R, Pollock B, Garver B, Barnett T Am J Lifestyle Med. 2022; 16(3):374-381.

PMID: 35706593 PMC: 9189589. DOI: 10.1177/15598276211006349.

Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults.

Zhou Z, Curtis A, Ernst M, Ryan J, Zoungas S, Wolfe R Eur J Clin Pharmacol. 2021; 78(3):467-476.

PMID: 34698889 PMC: 9993349. DOI: 10.1007/s00228-021-03239-1.

References

Jones P, Davidson M, Stein E, Bays H, McKenney J, Miller E . Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003; 92(2):152-60. DOI: 10.1016/s0002-9149(03)00530-7. View

Ohsfeldt R, Gandhi S, Fox K, Stacy T, McKenney J . Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice. Am J Manag Care. 2006; 12(15 Suppl):S412-23. View

Shepherd J, Blauw G, Murphy M, Bollen E, Buckley B, Cobbe S . Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002; 360(9346):1623-30. DOI: 10.1016/s0140-6736(02)11600-x. View

Colhoun H, Betteridge D, Durrington P, Hitman G, Neil H, Livingstone S . Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435):685-96. DOI: 10.1016/S0140-6736(04)16895-5. View

BRADFORD R, SHEAR C, CHREMOS A, Dujovne C, FRANKLIN F, Grillo R . Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol. 1994; 74(7):667-73. DOI: 10.1016/0002-9149(94)90307-7. View

Bays H . Statin safety: an overview and assessment of the data--2005. Am J Cardiol. 2006; 97(8A):6C-26C. DOI: 10.1016/j.amjcard.2005.12.006. View

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004; 44(3):720-32. DOI: 10.1016/j.jacc.2004.07.001. View

McKenney J, Davidson M, Jacobson T, Guyton J . Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006; 97(8A):89C-94C. DOI: 10.1016/j.amjcard.2006.02.030. View

. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339(19):1349-57. DOI: 10.1056/NEJM199811053391902. View

10.

Crouse 3rd J, Raichlen J, Riley W, Evans G, Palmer M, OLeary D . Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007; 297(12):1344-53. DOI: 10.1001/jama.297.12.1344. View

11.

Raina A, Pickering T, Shimbo D . Statin use in heart failure: a cause for concern?. Am Heart J. 2006; 152(1):39-49. DOI: 10.1016/j.ahj.2005.09.008. View

12.

Thompson P, Clarkson P, Rosenson R . An assessment of statin safety by muscle experts. Am J Cardiol. 2006; 97(8A):69C-76C. DOI: 10.1016/j.amjcard.2005.12.013. View

13.

Nissen S, Tuzcu E, Schoenhagen P, Brown B, Ganz P, Vogel R . Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004; 291(9):1071-80. DOI: 10.1001/jama.291.9.1071. View

14.

Schneck D, Knopp R, Ballantyne C, McPherson R, Chitra R, Simonson S . Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2002; 91(1):33-41. DOI: 10.1016/s0002-9149(02)02994-6. View

15.

Schwartz G, Olsson A, Ezekowitz M, Ganz P, Oliver M, Waters D . Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285(13):1711-8. DOI: 10.1001/jama.285.13.1711. View

16.

Taylor A, Kent S, Flaherty P, Coyle L, Markwood T, Vernalis M . ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002; 106(16):2055-60. DOI: 10.1161/01.cir.0000034508.55617.65. View

17.

PEARSON T, Laurora I, Chu H, Kafonek S . The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160(4):459-67. DOI: 10.1001/archinte.160.4.459. View

18.

Arca M . Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs. 2007; 67 Suppl 1:43-54. DOI: 10.2165/00003495-200767001-00005. View

19.

LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart J . Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352(14):1425-35. DOI: 10.1056/NEJMoa050461. View

20.

Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View